1. Home
  2. LSTA vs CGTX Comparison

LSTA vs CGTX Comparison

Compare LSTA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSTA
  • CGTX
  • Stock Information
  • Founded
  • LSTA 1980
  • CGTX 2007
  • Country
  • LSTA United States
  • CGTX United States
  • Employees
  • LSTA N/A
  • CGTX N/A
  • Industry
  • LSTA Misc Health and Biotechnology Services
  • CGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LSTA Health Care
  • CGTX Health Care
  • Exchange
  • LSTA Nasdaq
  • CGTX Nasdaq
  • Market Cap
  • LSTA 31.2M
  • CGTX 30.0M
  • IPO Year
  • LSTA N/A
  • CGTX 2021
  • Fundamental
  • Price
  • LSTA $2.60
  • CGTX $0.65
  • Analyst Decision
  • LSTA Strong Buy
  • CGTX Strong Buy
  • Analyst Count
  • LSTA 1
  • CGTX 6
  • Target Price
  • LSTA $15.00
  • CGTX $8.30
  • AVG Volume (30 Days)
  • LSTA 71.7K
  • CGTX 1.0M
  • Earning Date
  • LSTA 02-27-2025
  • CGTX 03-25-2025
  • Dividend Yield
  • LSTA N/A
  • CGTX N/A
  • EPS Growth
  • LSTA N/A
  • CGTX N/A
  • EPS
  • LSTA N/A
  • CGTX N/A
  • Revenue
  • LSTA N/A
  • CGTX N/A
  • Revenue This Year
  • LSTA N/A
  • CGTX N/A
  • Revenue Next Year
  • LSTA N/A
  • CGTX N/A
  • P/E Ratio
  • LSTA N/A
  • CGTX N/A
  • Revenue Growth
  • LSTA N/A
  • CGTX N/A
  • 52 Week Low
  • LSTA $2.19
  • CGTX $0.34
  • 52 Week High
  • LSTA $4.20
  • CGTX $2.95
  • Technical
  • Relative Strength Index (RSI)
  • LSTA 42.39
  • CGTX 45.88
  • Support Level
  • LSTA $2.45
  • CGTX $0.60
  • Resistance Level
  • LSTA $2.95
  • CGTX $0.82
  • Average True Range (ATR)
  • LSTA 0.32
  • CGTX 0.06
  • MACD
  • LSTA -0.07
  • CGTX -0.02
  • Stochastic Oscillator
  • LSTA 17.61
  • CGTX 27.63

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: